Literature DB >> 8034555

The molecular basis of normal HbA2 (type 2) beta-thalassemia in Greece.

M Tzetis1, J Traeger-Synodinos, E Kanavakis, A Metaxotou-Mavromati, C Kattamis.   

Abstract

Heterozygotes for beta-thalassemia usually have raised levels of HbA2, but in Greece about 5% of beta-thalassemia carriers are observed to have normal or borderline levels. It is postulated that such cases have mild beta+ thalassemia mutations or coinheritance of delta-thalassemia. We selected 18 heterozygotes with the hematological phenotype of normal HbA2 (type 2) beta thalassemia who were negative for the delta beta Corfu mutation, and screened them for previously defined Mediterranean beta-thalassemia and delta-thalassemia mutations. The coinheritance of beta and delta-thalassemia was demonstrated in four cases with the following genotypes: in cis beta+ IVSII -n745/delta+ 27, beta 0NS39/delta 059(-A), beta+ IVSI-n110/delta 059(-A) and in trans beta+ IVSI-n6 and delta+ 27. A further nine heterozygotes had mild beta(+)-thalassemia mutations (eight with the beta+ IVSI-n6 mutation, one with the beta+ polyA (A-->G) mutation). In four heterozygotes with severe beta-thalassemia chromosomes (2 beta+ IVSI-n110, 1 beta 0 FSC-6, 1 beta 0 IVSI-n1) no known delta-thalassemia mutations were observed. One case had a delta beta deletion chromosome. These results indicate that the hematological phenotype of normal HbA2 (type 2) beta-thalassemia in Greece is genetically heterogeneous; it is mainly associated with the delta beta Corfu mutation or coinheritance of beta and delta thalassemia mutations or with very mild beta(+)-thalassemia mutations, mainly beta+ IVSI-n6. In the rare cases with severe beta-thalassemia mutations, the normal levels of HbA2 may be due to coinheritance of as yet undefined delta thalassemia mutations.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8034555

Source DB:  PubMed          Journal:  Hematol Pathol        ISSN: 0886-0238


  3 in total

Review 1.  Carrier screening and genetic counselling in beta-thalassemia.

Authors:  Antonio Cao
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

2.  Significance of borderline HbA2 levels in β thalassemia carrier screening.

Authors:  Stacy Colaco; Roshan Colah; Anita Nadkarni
Journal:  Sci Rep       Date:  2022-03-30       Impact factor: 4.379

3.  Heterozygosity of the Complex Corfu δ0β+ Thalassemic Allele (HBD Deletion and HBB:c.92+5G>A) Revisited.

Authors:  Christos Kattamis; Myrto Skafida; Polyxeni Delaporta; Christina Vrettou; Joanne Traeger-Synodinos; Christalena Sofocleous; Antonis Kattamis
Journal:  Biology (Basel)       Date:  2022-03-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.